183 related articles for article (PubMed ID: 17694494)
1. Production and tumour uptake of [64Cu]Pyruvaldehyde-bis (N4-methylthiosemicarbazone) for PET and/or therapeutic purposes.
Jalilian AR; Rowshanfarzad P; Kamrani YY; Shafaii K; Mirzaii M
Nucl Med Rev Cent East Eur; 2007; 10(1):6-11. PubMed ID: 17694494
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and formulation of [
Green MA; Mathias CJ
Appl Radiat Isot; 2022 Apr; 182():110119. PubMed ID: 35093818
[TBL] [Abstract][Full Text] [Related]
3. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Liu J; Hajibeigi A; Ren G; Lin M; Siyambalapitiyage W; Liu Z; Simpson E; Parkey RW; Sun X; Oz OK
J Nucl Med; 2009 Aug; 50(8):1332-9. PubMed ID: 19617332
[TBL] [Abstract][Full Text] [Related]
4. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
Lewis JS; McCarthy DW; McCarthy TJ; Fujibayashi Y; Welch MJ
J Nucl Med; 1999 Jan; 40(1):177-83. PubMed ID: 9935074
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging.
Jalilian AR; Rostampour N; Rowshanfarzad P; Shafaii K; Kamali-Dehghan M; Akhlaghi M
Acta Pharm; 2009 Mar; 59(1):45-55. PubMed ID: 19304557
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM.
Mathias CJ; Welch MJ; Raichle ME; Mintun MA; Lich LL; McGuire AH; Zinn KR; John EK; Green MA
J Nucl Med; 1990 Mar; 31(3):351-9. PubMed ID: 2308007
[TBL] [Abstract][Full Text] [Related]
9. Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM.
Wallhaus TR; Lacy J; Whang J; Green MA; Nickles RJ; Stone CK
J Nucl Med; 1998 Nov; 39(11):1958-64. PubMed ID: 9829589
[TBL] [Abstract][Full Text] [Related]
10. Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET.
Green MA; Klippenstein DL; Tennison JR
J Nucl Med; 1988 Sep; 29(9):1549-57. PubMed ID: 3261785
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of copper radiopharmaceuticals with mixed bis(thiosemicarbazone) ligands.
Ackerman LJ; West DX; Mathias CJ; Green MA
Nucl Med Biol; 1999 Jul; 26(5):551-4. PubMed ID: 10473194
[TBL] [Abstract][Full Text] [Related]
12. Performance of a 62Zn/62Cu generator in clinical trials of PET perfusion agent 62Cu-PTSM.
Haynes NG; Lacy JL; Nayak N; Martin CS; Dai D; Mathias CJ; Green MA
J Nucl Med; 2000 Feb; 41(2):309-14. PubMed ID: 10688116
[TBL] [Abstract][Full Text] [Related]
13. Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin.
Mathias CJ; Bergmann SR; Green MA
J Nucl Med; 1995 Aug; 36(8):1451-5. PubMed ID: 7629593
[TBL] [Abstract][Full Text] [Related]
14. Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion.
Green MA; Mathias CJ; Welch MJ; McGuire AH; Perry D; Fernandez-Rubio F; Perlmutter JS; Raichle ME; Bergmann SR
J Nucl Med; 1990 Dec; 31(12):1989-96. PubMed ID: 2266398
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cell-labeling methods with ¹²⁴I-FIAU and ⁶⁴Cu-PTSM for cell tracking using chronic myelogenous leukemia cells expressing HSV1-tk and firefly luciferase.
Park JJ; Lee TS; Son JJ; Chun KS; Song IH; Park YS; Kim KI; Lee YJ; Kang JH
Cancer Biother Radiopharm; 2012 Dec; 27(10):719-28. PubMed ID: 23009582
[TBL] [Abstract][Full Text] [Related]
16. Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins.
Basken NE; Mathias CJ; Lipka AE; Green MA
Nucl Med Biol; 2008 Apr; 35(3):281-6. PubMed ID: 18355683
[TBL] [Abstract][Full Text] [Related]
17. In vivo tracking of Th1 cells by PET reveals quantitative and temporal distribution and specific homing in lymphatic tissue.
Griessinger CM; Kehlbach R; Bukala D; Wiehr S; Bantleon R; Cay F; Schmid A; Braumüller H; Fehrenbacher B; Schaller M; Eichner M; Sutcliffe JL; Ehrlichmann W; Eibl O; Reischl G; Cherry SR; Röcken M; Pichler BJ; Kneilling M
J Nucl Med; 2014 Feb; 55(2):301-7. PubMed ID: 24434289
[TBL] [Abstract][Full Text] [Related]
18. A potential copper radiopharmaceutical for imaging the heart and brain: copper-labeled pyruvaldehyde bis(N4-methylthiosemicarbazone).
Green MA
Int J Rad Appl Instrum B; 1987; 14(1):59-61. PubMed ID: 3583756
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model.
Young H; Carnochan P; Zweit J; Babich J; Cherry S; Ott R
Eur J Nucl Med; 1994 Apr; 21(4):336-41. PubMed ID: 8005157
[TBL] [Abstract][Full Text] [Related]
20. Tissue blood flow estimation with copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) and PET.
Young H; Carnochan P; Zweit J; Babich J; Cherry S; Ott R
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):89-91. PubMed ID: 7632775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
